Design and Formulation of Dual-Action Nanoparticles for Synergistic Cancer Therapy

Abstract

Suboptimal tumour targeting, systemic toxicity, and drug resistance are three of the major obstacles in cancer treatment. To improve accuracy of tumour targeting, effectiveness, and safety, dual-action nanoparticles combine two or more therapeutic processes onto one platform. Designing and formulating CS-g-PNIPAAm nanoparticles loaded with oxaliplatin is the main focus of this investigation. The nanoparticles release their medications preferentially in tumor-specific acidic and high-temperature settings, demonstrating thermo- and pH-responsiveness. High drug-loading efficiency (82.8%) and great stability with low damage to normal cells were obtained by the nanoparticles by direct loading and self-assembly procedures. Research in vitro has shown that compared to free medicines, they had better cytotoxicity against cancer cells, improved cellular absorption, and effective drug release under tumor-relevant circumstances. These results highlight the promise of dual-action nanoparticles for improving targeted cancer therapy and escaping the constraints of traditional therapies.